Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-43: (Canceled)

44. (New) A method of identifying a compound as an agonist for an EDG receptor comprising the steps of:
    a. culturing cells which express an EDG receptor in medium with low-serum or medium designed to reduce basal levels of NF-κB activation;
    b. contacting said cultured cells with a compound to be tested for agonist activity at said EDG receptor; and
    c. measuring a response indicative of the degree of NF-κB activation.
45. (New) The method according to claim 44 wherein said receptor is selected from the group consisting of EDG-2, EDG-3, EDG-4, EDG-5 and EDG-6.
46. (New) A method of identifying a compound as an agonist for an EDG receptor comprising the steps of:
    a. culturing cells which express said an EDG receptor in a medium with low-serum or medium designed to reduce basal levels of IL-8 production;

b. contacting said cultured cells with a candidate compound to be tested for agonist activity at said receptor; and

c. measuring a response indicative of the degree of IL-8 production.

47. (New) The method according to claim 46 wherein said receptor is selected from the group consisting of EDG-2, EDG-3, EDG-4, EDG-5, and EDG-6.

48. (New) A method of identifying a compound as an antagonist for an EDG receptor comprising the steps of:

a. culturing cells which express an EDG receptor in a medium with low-serum or medium designed to reduce basal levels of NF-κB activation;

b. contacting said cultured cells with a mixture comprising an agonist and a compound to be tested for antagonist activity at said receptor, wherein said agonist is selected from LL or 20% FBS; and

c. measuring a response indicative of the degree of NF-κB activation.

49. (New) The method of claim 48 wherein said receptor is selected from the group consisting of EDG-2, EDG-3, EDG-4, EDG-5 and EDG-6.

50. (New) A method of identifying a compound as an antagonist for an EDG receptor comprising the steps of:

a. culturing cells which express an EDG receptor in a medium with low-serum or medium designed to reduce basal levels of IL-8 production;

b. contacting said cultured cells with a mixture comprising an agonist and a compound to be tested for antagonist activity at said receptor, wherein said agonist is an LL or 20% FBS; and

c. measuring a response indicative of the degree of IL-8 product.

51. (New) The method of claim 50 wherein said receptor is selected from the group consisting of EDG-2, EDG-3, EDG-4, EDG-5 and EDG-6.

52. (New) A method of identifying a compound as an agonist or antagonist of an EDG receptor as identified by the amino acid sequence selected from the group consisting of (a) the amino acid sequence comprising SEQ ID NO: 2 and (b) the amino acid sequence comprising SEQ ID NO:4, comprising the steps of:

a. culturing cells which express an EDG receptor;

b. contacting said cultured cells with a compound to be tested for agonist or antagonist activity at said receptor; and

c. measuring an appropriate response indicative of the degree of agonist or antagonist activity.

53. (New) The method according to claim 52, wherein the compound in step (b) is to be tested for agonist activity at the receptor, and step (C) measures the degree of agonist activity.

54. (New) The method according to claim 52, wherein the compound in step (b) is to be tested for antagonist activity at the receptor, and step (c) measures the degrees of antagonist activity.

55. (New) The method according to claim 52, wherein the response measured in step (c) is selected from activation of NFκb, activation of Serum Response Element (SRE) and AP-1, increase in intracellular calcium levels, modulation of cellular cyclic AMP levels and $GTP_{\gamma}S$ binding.

56. (New) The method according to claim 55, wherein the response in step (c) is activation of NFκB or Activation of Serum Response Element (SRE), and is measured through a reporter assay.

57. (New) The method according to claim 55, wherein the response in step (c) is activation of NFκB and is measured by determining the level of cytokines production.

58. (New) The method according to claim 57, wherein the cytokines are selected from the group consisting of Il-8, Il-6, and MCP.

59. (New) The method according to claim 58, wherein the level of cytokine production is determined using ELISA.